Table 1 Baseline characteristics for patients with or without MACCEs
Variables | Overall (N = 8835) | Non-MACCE (N = 8161) | MACCE (N = 674) | P value |
|---|---|---|---|---|
Four subgroups | < 0.001 | |||
NLR-L/Non-T2DM | 3656 (41.4) | 3419 (41.9) | 237 (35.2) | |
NLR-H/Non-T2DM | 1139 (12.9) | 1066 (13.1) | 73 (10.8) | |
NLR-L/T2DM | 3063 (34.7) | 2811 (34.4) | 252 (37.4) | |
NLR-H/T2DM | 977 (11.1) | 865 (10.6) | 112 (16.6) | |
Baseline characteristics | ||||
Age, years | 58.38 ± 10.19 | 58.24 ± 10.16 | 60.08 ± 10.41 | < 0.001 |
Male | 6805 (77.0) | 6286 (77.0) | 519 (77.0) | 1.000 |
BMI, kg/m2 | 25.92 ± 3.20 | 25.92 ± 3.21 | 25.92 ± 3.11 | 0.776 |
T2DM | 4040 (45.7) | 3676 (45.0) | 364 (54.0) | < 0.001 |
Hypertension | 5712 (64.7) | 5247 (64.3) | 465 (69.0) | 0.016 |
Dyslipidemia | 5912 (66.9) | 5449 (66.8) | 463 (68.7) | 0.328 |
Smoking history | 5055 (57.2) | 4675 (57.3) | 380 (56.4) | 0.678 |
Previous MI | 1678 (19.0) | 1524 (18.7) | 154 (22.8) | 0.009 |
Previous PCI | 2028 (23.0) | 1848 (22.6) | 180 (26.7) | 0.018 |
Previous CABG | 352 (4.0) | 318 (3.9) | 34 (5.0) | 0.173 |
Previous stroke | 927 (10.5) | 829 (10.2) | 98 (14.5) | < 0.001 |
Previous PAD | 654 (7.4) | 601 (7.4) | 53 (7.9) | 0.690 |
Clinical presentation | 0.709 | |||
SAP | 3619 (41.0) | 3348 (41.0) | 271 (40.2) | |
ACS | 5216 (59.0) | 4813 (59.0) | 403 (59.8) | |
Laboratory tests | ||||
Neutrophils, *109/L | 4.27 ± 1.57 | 4.25 ± 1.55 | 4.51 ± 1.76 | < 0.001 |
Lymphocyte, *109/L | 1.95 ± 0.64 | 1.95 ± 0.64 | 1.97 ± 0.65 | 0.306 |
NLR | 2.44 ± 1.57 | 2.43 ± 1.57 | 2.55 ± 1.54 | 0.051 |
FBG, mmol/L | 6.28 ± 2.25 | 6.25 ± 2.20 | 6.67 ± 2.77 | < 0.001 |
HbA1c, % | 6.62 ± 1.25 | 6.61 ± 1.25 | 6.77 ± 1.24 | < 0.001 |
TG, mmol/L | 1.78 ± 1.08 | 1.78 ± 1.08 | 1.75 ± 1.03 | 0.420 |
TC, mmol/L | 4.20 ± 1.06 | 4.20 ± 1.07 | 4.21 ± 1.02 | 0.702 |
HDL-C, mmol/L | 1.04 ± 0.30 | 1.04 ± 0.30 | 1.05 ± 0.30 | 0.670 |
LDL-C, mmol/L | 2.49 ± 0.90 | 2.49 ± 0.91 | 2.49 ± 0.87 | 0.825 |
hsCRP, mg/L | 3.03 ± 3.60 | 3.00 ± 3.59 | 3.33 ± 3.71 | 0.002 |
Creatinine, μmol/L | 75.25 ± 15.47 | 75.18 ± 15.43 | 75.98 ± 15.89 | 0.279 |
eGFR, mL/min/1.73 m2 | 102.84 ± 22.10 | 102.94 ± 21.96 | 101.53 ± 23.69 | 0.050 |
LVEF, % | 63.08 ± 7.06 | 63.16 ± 7.01 | 62.15 ± 7.60 | 0.001 |
Medications | ||||
DAPT | 8636 (97.7) | 7975 (97.7) | 661 (98.1) | 0.650 |
β-blocker | 7955 (90.0) | 7333 (89.9) | 622 (92.3) | 0.050 |
CCB | 4353 (49.3) | 3998 (49.0) | 355 (52.7) | 0.072 |
Statins | 8484 (96.0) | 7836 (96.0) | 648 (96.1) | 0.955 |
Nitrate | 8648 (97.9) | 7987 (97.9) | 661 (98.1) | 0.831 |
Coronary procedural data | ||||
LM/three-vessel disease | 3941 (44.6) | 3582 (43.9) | 359 (53.3) | < 0.001 |
Chronic total occlusion | 726 (8.2) | 656 (8.0) | 70 (10.4) | 0.039 |
Bifurcation lesions | 1785 (20.2) | 1661 (20.4) | 124 (18.4) | 0.244 |
Moderate to severe calcification | 1560 (17.7) | 1417 (17.4) | 143 (21.2) | 0.014 |
Number of treated vessels | 1.43 ± 0.68 | 1.42 ± 0.67 | 1.52 ± 0.78 | 0.003 |
Number of stents | 1.93 ± 1.06 | 1.92 ± 1.06 | 2.02 ± 1.04 | 0.003 |
IABP | 84 (1.0) | 64 (0.8) | 20 (3.0) | < 0.001 |
SYNTAX score | 11.91 ± 7.67 | 11.82 ± 7.61 | 13.01 ± 8.25 | < 0.001 |